Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma (Q74204403)
Jump to navigation
Jump to search
scientific article published on 01 July 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma |
scientific article published on 01 July 2000 |
Statements
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma (English)
G A Wiseman
C A White
M Stabin
W L Dunn
W Erwin
M Dahlbom
A Raubitschek
K Karvelis
T Schultheiss
T E Witzig
R Belanger
S Spies
D H Silverman
J R Berlfein
E Ding
A J Grillo-López